Tour de France director Christian Prudhomme has called upon cycling's authorities to quickly resolve the case of Chris Froome's Adverse Analytical Finding for salbutamol.
Froome is currently cooperating with the UCI in the matter, which he says is not an anti-doping rule violation. The Team Sky rider has long used the drug to control his asthma.
Under UCI rules, cases like Froome's would not be made public unless they resulted in a rule violation. But the information was leaked to the press earlier this month, leading to a media storm that could drag out well into next season - a situation Prudhomme wishes to avoid.
ADVERTISEMENT
"We want the situation to be cleared up, to get out of the darkness and ambiguity," Prudhomme told France Info TV on Friday. "We obviously want an investigation to be conducted, and we don't want it to last for months and months, so we can have an answer from the UCI as soon as possible next season."
Because athletes vary widely in their metabolism of the drug, WADA rules allow athletes who test over the threshold limit to undergo a controlled study to attempt to demonstrate that the levels were not the result of an anti-doping rule violation, such as taking more of the allowed dose of 800 micrograms over 12 hours or 1,600mcg in 24 hours, or using a prohibited oral or injection delivery route.
One of Froome's urine samples from the Vuelta a España tested at twice the allowed WADA limit for the asthma drug. Because of the anti-doping rules surrounding the so-called "specified substances", Froome is not subject to a provisional suspension while his case is under examination.
- Chris Froome returns adverse analytical finding for salbutamol
- Will Chris Froome's salbutamol result sink Team Sky?
- A lot of explaining to do: The questions raised by the Chris Froome salbutamol case
- Timeline of Chris Froome's adverse analytical finding for salbutamol
You can read more at Cyclingnews.com
via Cyclingnews Latest News http://ift.tt/2kG5npp
No comments:
Post a Comment